FRM
OCUL icon

Fox Run Management’s Ocular Therapeutix OCUL Stock Holding History

Fox Run Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$692K Buy
70,446
+59,491
+543% +$539K 0.11% 344
2026
Q1 		$81.1K Sell
10,955
-42,137
-79% -$402K 0.01% 848
2025
Q4 		$645K Buy
+53,092
New +$645K 0.1% 392
2022
Q4 		– Sell
-25,597
Closed -$106K – 810
2022
Q3 		$106K Buy
+25,597
New +$129K 0.04% 545
2022
Q1 		– Sell
-12,752
Closed -$89K – 644
2021
Q4 		$89K Buy
+12,752
New +$99K 0.05% 426

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's OCUL Position: Q2 2026 in Review

Fox Run Management increased its Ocular Therapeutix (OCUL) stake by 543% in Q2 2026, buying an estimated $539K and bringing the position to 70,446 shares worth $692K. The position accounts for 0.11% of the portfolio, ranked #344.

Fox Run Management first reported a position in OCUL in Q4 2021 and has held it in 5 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Fox Run Management held 70,446 shares of Ocular Therapeutix worth $692K as of Q2 2026.
  • Fox Run Management bought 59,491 Ocular Therapeutix shares in Q2 2026, an estimated $539K.
  • Ocular Therapeutix made up 0.11% of Fox Run Management's portfolio in Q2 2026, its #344 holding.
  • Fox Run Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 5 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.